

Axel Dignass

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7048491/publications.pdf>

Version: 2024-02-01

40
papers

5,040
citations

361045

20
h-index

301761

39
g-index

45
all docs

45
docs citations

45
times ranked

5517
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. <i>Journal of Medical Economics</i> , 2021, 24, 279-290.	1.0	7
2	Overcoming the barriers to dissemination and implementation of quality measures for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) position statement. <i>United European Gastroenterology Journal</i> , 2021, 9, 120-126.	1.6	4
3	Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. <i>Expert Review of Hematology</i> , 2021, , 1-2.	1.0	0
4	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	0.6	6
5	Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 316-322.	0.6	13
6	Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. <i>Journal of Medical Economics</i> , 2020, 23, 415-427.	1.0	11
7	Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 804-813.	1.6	17
8	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	4.9	58
9	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX [®] (Cortiment [®] MMX [®]) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2019, 7, 1171-1182.	1.6	9
10	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, 1032-1043.e1.	0.6	48
11	Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. <i>Advances in Therapy</i> , 2019, 36, 1817-1820.	1.3	0
12	Indirect comparison of vedolizumab and adalimumab for biologic-naïve patients with ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 178-187.	0.6	3
13	Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 442-448.	0.6	12
14	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	0.6	331
15	A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 670-676.	0.6	28
16	Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1059-1065.	0.6	16
17	Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. <i>International Journal of Chronic Diseases</i> , 2018, 2018, 1-11.	1.9	134
18	Review article: treating a target for inflammatory bowel disease-associated anaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 610-617.	1.9	28

#	ARTICLE	IF	CITATIONS
19	An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 347-357.	1.9	157
20	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
21	Editorial: which iron preparation for patients with IBD? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 195-196.	1.9	3
22	Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1303-1318.	1.9	87
23	Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 705-706.	1.9	4
24	Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1721-1737.	0.9	25
25	Letter: inconsistency in reporting of hypophosphataemia after intravenous iron authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 643-644.	1.9	0
26	Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 812-820.	0.6	35
27	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	0.6	425
28	Letter: leucocytapheresis as a nonpharmacologic treatment for patients with ulcerative colitis during pregnancy authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 235-236.	1.9	0
29	Editorial: the management of IBD during pregnancy and lactation - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1248-1248.	1.9	0
30	Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 970-980.	0.6	37
31	Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 991-1008.	1.9	48
32	Complementary Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2014, 15, 1079-1088.	1.0	5
33	Letter: inflammatory bowel disease guidelines and conflicts of interest. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 445-445.	1.9	0
34	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 991-1030.	0.6	1,106
35	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 965-990.	0.6	715
36	Interferon- β modulates intestinal epithelial cell function in-vitro through a TGF β -dependent mechanism. <i>Regulatory Peptides</i> , 2011, 168, 27-31.	1.9	5

#	ARTICLE	IF	CITATIONS
37	Clinical trial: five or ten cycles of granulocyteâ€“monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1286-1295.	1.9	31
38	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 28-62.	0.6	1,247
39	Management of Inflammatory Bowel Diseases during Pregnancy. <i>Digestive Diseases</i> , 2009, 27, 341-346.	0.8	16
40	Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 762-769.	2.4	130